Ritesh International expands capacity by 50% with ₹7 crore capex
Ritesh International Limited is expanding its Ahmedgarh manufacturing facility by 50%, raising daily output from 80 to 120 metric tons. The ₹7 crore investment is primarily funded by internal accruals (₹6 crore) with minimal bank debt (₹1 crore). Commercial production is targeted for Q1 FY27-28, aiming to capitalize on high utilization rates and growing demand for stearic acid and related products.

*this image is generated using AI for illustrative purposes only.
Ritesh International has approved a 50% expansion of its manufacturing capacity at its Ahmedgarh facility to address rising demand for stearic acid, fatty acid, and glycerin. The company plans to increase its daily production capability from 80 metric tons to 120 metric tons, with commercial operations expected to begin in Q1 FY27-28.
The expansion involves a total capital expenditure of ₹7 crore. Financing will be structured through a mix of long-term bank loans amounting to approximately ₹1 crore and internal accruals covering the balance of ₹6 crore. The project is scheduled for completion within approximately eight months.
Strategic Implications
Ritesh Arora, Chairman and Managing Director, stated that existing facilities are operating near peak capacity utilization. The expansion aims to strengthen market share and enhance operating margins by meeting surging customer demand across core markets. The company emphasized that leveraging debt financing alongside internal accruals allows it to maintain a healthy balance sheet while positioning for sustained revenue growth.
What the Numbers Show
The funding structure reveals a strong reliance on internal resources, with internal accruals accounting for approximately 86% of the total ₹7 crore capital expenditure. This suggests limited incremental leverage pressure on the balance sheet, as only ₹1 crore is being raised through external long-term bank debt. This capital-light approach to expansion indicates the company’s current cash generation capabilities are sufficient to support significant capacity additions without heavily diluting equity or increasing interest burden proportionately.
| Project Metric | Details |
|---|---|
| Capacity Increase | 50% (from 80 to 120 metric tons/day) |
| Total Capex | ₹7 crore |
| Funding Source | ₹6 crore internal accruals, ₹1 crore bank debt |
| Timeline | Approx. 8 months |
| Commercial Start | Q1 FY27-28 |
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rijul Arora, CFO and Wholetime Director, signed the intimation on August 17, 2026.
Historical Stock Returns for Ritesh International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.25% | -0.60% | +23.81% | +28.33% | +172.73% | +157.43% |
How will the 50% capacity expansion impact Ritesh International's operating margins given the current pricing trends for stearic acid and glycerin in FY27-28?
What is the company's strategy to maintain its near-peak capacity utilization rates once the new 120 metric tons/day production capability comes online?
Could the reliance on internal accruals for 86% of the capex limit Ritesh International's ability to pursue larger strategic acquisitions or diversification projects in the near term?


































